City of Hope | Strategic Alliance Partners

August 28, 2024

A medical oncologist discusses the value of PD-L1 as a biomarker in the treatment of patients with nasopharyngeal carcinoma.

August 28, 2024

Victoria M. Villaflor, MD, provides insights on the role of immune checkpoint inhibitors in treating nasopharyngeal carcinoma, focusing on the JUPITER and POLARIS-2 clinical trials.

August 22, 2024

Key opinion leaders analyze the potential significance of preliminary data on BGB-16673, a BTK inhibitor degrader, in anticipation of its presentation at EHA 2024.

August 22, 2024

The panel explores potential applications and impact of BTK inhibitor degraders as an emerging class of novel agents for treating relapsed/refractory chronic lymphocytic leukemia.

August 22, 2024

Geoffrey Shouse, DO, PhD, discusses the importance of performing next-generation sequencing in patients with follicular lymphoma.

August 21, 2024

Drs Park and Kasi delve into the shift toward neoadjuvant immunotherapy and the use of ctDNA as a prognostic tool in colorectal cancer.

August 21, 2024

Shravan Kandula, MD, reviews the current guidelines for the treatment of patients with nasopharyngeal carcinoma.

August 21, 2024

Experts on nasopharyngeal carcinoma (NPC) provide an overview of the disease, highlighting its incidence, how it’s differentiated from other head and neck cancers, and the benefits of multidisciplinary care.

August 20, 2024

Geoffrey Shouse, DO, PhD, discusses adverse effects associated with targeted therapies used to treat patients with follicular lymphoma.

August 15, 2024

Key opinion leaders analyze the implications of the FDA's accelerated approval for lisocabtagene maraleucel (liso-cel) in chronic lymphocytic leukemia, based on promising results from the TRANSCEND CLL 004 trial.

August 15, 2024

A medical expert offers commentary on the recent FDA accelerated approval of pirtobrutinib, discussing the implications of the BRUIN trial findings that supported this decision for chronic lymphocytic leukemia treatment.

August 15, 2024

Geoffrey Shouse, DO, PhD, discusses the benefits of utilizing targeted therapy approaches in the treatment of patients with follicular lymphoma.

August 13, 2024

Geoffrey Shouse, DO, PhD, discusses currently available targeted therapies for the management of follicular lymphoma.

August 08, 2024

August 06, 2024

Alexey Danilov, MD, PhD, discusses the importance of using BTK as a target, as well as recent updates on BTK degraders within the CLL treatment paradigm.

August 05, 2024

Alexey Danilov, MD, PhD, highlights non-chemotherapy options for the treatment of mantle cell lymphoma and expands on ongoing research in hematologic malignancies.

July 18, 2024

Tycel Phillips, MD, discusses the evolution of treatment for patients with myelodysplastic syndromes, highlighting the future of this treatment paradigm.

July 15, 2024

Preliminary data from a first-in-human phase 1 trial using a CAR T-cell therapy developed by City of Hope researchers has been published in Nature Medicine.

July 11, 2024

Sumanta Kumar Pal, MD, FASCO, discusses preliminary findings from a phase 1 dose-escalation study of DFF332 in patients with advanced ccRCC.

July 11, 2024

Amrita Krishnan, MD, discusses the characteristics and factors associated with a higher risk of early relapse for patients with multiple myeloma.